Aging is a time-dependent inevitable process, in which cellular homeostasis is affected, which has an
impact on tissue function. This represents a risk factor for the development of numerous non-transmissible diseases.
In consequence, the scientific community continues to search for therapeutic measures capable of improving
quality of life and delaying cellular aging. At the center of this research is metformin, a widely used drug in
Type 2 Diabetes Mellitus treatment that has a reduced adverse effects profile. Furthermore, there is evidence that
this drug has beneficial health effects that go beyond its anti-hyperglycemic properties. Among these effects, its
geronto-protection capability stands out. There is growing evidence that points out to an increased life expectancy
as well as the quality of life in model organisms treated with metformin. Therefore, there is an abundance of
research centered on elucidating the mechanism through which metformin has its anti-aging effects. Among
these, the AMPK, mTORC1, SIRT1, FOXO, NF.kB, and DICER1 pathways can be mentioned. Furthermore,
studies have highlighted the possibility of a role for the gut microbiome in these processes. The next step is the
design of clinical essays that have as a goal evaluating the efficacy and safety of metformin as an anti-aging drug
in humans to create a paradigm in the medical horizon. The question being if metformin is, in fact, the new antiaging
therapy in humans?